Schultheis B, Krämer A, Willer A, Hegenbart U, Goldschmidt H, Hehlmann R
III Medizinische Klinik, Klinikum Mannheim, Universität Heidelberg, Mannheim, Germany.
Leukemia. 1999 Dec;13(12):2099-103. doi: 10.1038/sj.leu.2401609.
Recently, p73, a protein with structural and functional similarities to p53, an extensively studied tumor suppressor gene, has been cloned. After being mapped to the chromosomal region 1p35-1p36, it has been postulated to act as a tumor suppressor gene, too, as this region is altered in several human malignancies. Deletions of the short arm of chromosome 1 have frequently been described in multiple myeloma (MM) whereas structural abnormalities of the 17p13 region including p53 are rare events in this disease. Since it has been proposed that especially neoplasias lacking p53 alterations might show a loss of heterozygosity at 1p35-1p36, we studied the frequency of p53 and p73 deletions in bone marrow mononuclear cells of 68 patients with MM, two patients with monoclonal gammopathy of undetermined significance and four patients with plasma cell leukemia. Dual-color fluorescence in situ hybridization (FISH) for p53 and p73 was performed using commercially available DNA probes for 17p13.3 and the microsatellite marker D1Z2, respectively. Centromeric DNA probes served to distinguish gene deletions from whole chromosome losses. In contrast to recently published FISH results, we only detected heterozygous p53 deletions in eight out of the 74 patients, three of them showing a monosomy 17. Heterozygous deletions of the D1Z2 region at 1p36 were found in six cases with one patient having a monosomy 1. Neither homozygous deletions of either chromosomal region nor nullisomies 1 or 17 could be detected. These results argue against a major role of p73 deletions in MM. As MM patients with 1p structural abnormalities have a significantly poorer survival rate than those with normal karyotypes, the role of other putative tumor suppressor genes located at the chromosomal region 1p36 in the pathogenesis of MM has to be determined.
最近,p73已被克隆,它是一种与p53在结构和功能上相似的蛋白质,p53是一个经过广泛研究的肿瘤抑制基因。在被定位到染色体区域1p35 - 1p36后,人们推测它也作为肿瘤抑制基因发挥作用,因为该区域在几种人类恶性肿瘤中发生了改变。1号染色体短臂的缺失在多发性骨髓瘤(MM)中经常被描述,而包括p53在内的17p13区域的结构异常在这种疾病中是罕见事件。由于有人提出,尤其是缺乏p53改变的肿瘤可能在1p35 - 1p36处显示杂合性缺失,我们研究了68例MM患者、2例意义未明的单克隆丙种球蛋白病患者和4例浆细胞白血病患者骨髓单个核细胞中p53和p73缺失的频率。分别使用市售的针对17p13.3的DNA探针和微卫星标记D1Z2对p53和p73进行双色荧光原位杂交(FISH)。着丝粒DNA探针用于区分基因缺失和整条染色体丢失。与最近发表的FISH结果相反,我们在74例患者中仅检测到8例杂合性p53缺失,其中3例显示17号染色体单体。在6例中发现了1p36处D1Z2区域的杂合性缺失,1例患者有1号染色体单体。未检测到任何一个染色体区域的纯合性缺失或1号或17号染色体缺体。这些结果表明p73缺失在MM中不起主要作用。由于具有1号染色体结构异常的MM患者的生存率明显低于核型正常的患者,位于染色体区域1p36的其他假定肿瘤抑制基因在MM发病机制中的作用必须加以确定。